AstraZeneca’s Lynparza (ingredient: olaparib) obtained additional indication for combination therapy with bevacizumab in the first-line maintenance treatment of ovarian cancer in Korea....The Ministry of Food and Drug Safety granted the use of Lynparza in combination with bevacizumab as the maintenance therapy for adult patients with HRD-positive advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who responded to the first-line combo of platinum-based chemotherapy and bevacizumab.

Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated:...in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status...

Lynparza in combination with bevacizumab is indicated for the...maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinumbased chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either...a deleterious or suspected deleterious BRCA mutation

Lynparza in combination with bevacizumab is indicated for the:...maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability...

Olaparib plus bevacizumab is recommended for use within the Cancer Drugs Fund as an option for maintenance treatment of advanced (International Federation of Gynecology and Obstetrics [FIGO] stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults when...the cancer is associated with homologous recombination deficiency (HRD).

Eligible patients were 18 years of age or older and had newly diagnosed advanced (International Federation of Gynecology and Obstetrics [FIGO] stage III or IV), high-grade serous or endometrioid ovarian cancer, primary peritoneal cancer, or fallopian-tube cancer....The duration of investigator-assessed progression-free survival was significantly longer in the olaparib group than in the placebo group (median, 22.1 months vs. 16.6 months; hazard ratio for disease progression or death, 0.59; 95% CI, 0.49 to 0.72; P<0.001)